Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

US11897951B2 · kind B2 · utility

Assignees

• Ablynx N.V. · BE
• Sanofi · FR

Inventors

• Heidi Rommelaere · Wondelgem, BE
• Christian Asbrand · Frankfurt am Main, DE
• Nadine Biesemann · Zwijnaarde, BE
• Ann Brigé · Ertvelde, BE
• Sigrid Cornelis · Gent, BE
• Karen Heyninck · Scheldewindeke, BE
• Eric Lorent · Zwijnaarde, BE
• Shanna Van Zwam · Wondelgem, BE

Key dates

• Filing date: Dec 17, 2021
• Grant date: Feb 13, 2024
• Expiry date: Dec 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-α and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.